The global bleeding disorder community received an advance look at new international guidelines for the management of hemophilia at the WFH Virtual Summit 2020, at...
The development of inhibitory antibodies to therapeutic FVIII in up to 40% of severe hemophilia A (HA) patients is a major complication in the treatment...
Montreal, July 21, 2020 – The Canadian Hemophilia Society has in recent days made submissions to both CADTH (Canadian Agency for Drugs and Technologies in...
Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...
